NR2B Selective Ligands for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NR2B NMDA receptor antagonists have limited therapeutic value due to low bioavailability, poor pharmacokinetics, and lack of selectivity, leading to adverse effects such as cardiac arrhythmias, highlighting an unmet need for NR2B-selective negative allosteric modulators with improved tolerability.
Innovation Solution
Development of novel compounds of formula I, which are ligands for the NR2B receptor, specifically designed to target the N-terminal domain with a favorable pharmacokinetic profile and selectivity, including phenyl and pyridinyl substitutions, and various prodrug moieties to enhance bioavailability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NMDA antagonists such as Ketamine are used, then rapid and enduring antidepressant properties are achieved, but CNS side effects including dissociative effects and cardiac arrhythmias occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that selectively target the NR2B subunit of NMDA receptors. The compounds contain specific structural features including a piperidine or piperazine ring (ring A), a linker (X), and aromatic substituents (Ar1 and Ar2) that confer selectivity for NR2B over other NMDA receptor subunits and hERG channels, thereby achieving antidepressant efficacy while reducing off-target side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as the linker length (C1-C3 alkylene), substituent types (halo, alkyl, haloalkyl, haloalkoxy), and ring structures to optimize the balance between NR2B selectivity, hERG channel blockade avoidance, and pharmacokinetic properties including bioavailability and half-life
2Reliability
If NR2B-selective negative allosteric modulators are developed, then selectivity against hERG ion channel is improved, but low bioavailability and poor pharmacokinetics remain problematic
Solution Approach 1:
The patent applies parameter changes by optimizing physicochemical parameters of the compounds including molecular weight, lipophilicity (logP), hydrogen bonding capacity, and structural flexibility to improve oral bioavailability and pharmacokinetic profile while maintaining NR2B selectivity. The specific structural parameters in formula I are tuned to achieve favorable absorption and distribution characteristics
Solution Approach 2:
The patent uses prodrug moieties as intermediaries that are administered orally and then metabolized in vivo to release the active NR2B-selective compound. The prodrug approach mediates between the need for oral administration and the requirement for the compound to have specific structural features for NR2B selectivity, thereby improving bioavailability
3Object-affected harmful factors
If Traxoprodil is used as an NR2B-selective antagonist, then sustained antidepressant response and improved side effect profile are achieved, but low bioavailability and poor pharmacokinetics hinder development
Solution Approach 1:
The patent applies copying by designing new compounds (formula I) that replicate the favorable pharmacological profile of Traxoprodil (NR2B selectivity and improved side effect profile) while correcting its pharmacokinetic deficiencies. The compounds copy the successful pharmacological strategy of NR2B-selective negative allosteric modulation while incorporating structural modifications to improve absorption and metabolic stability
Data Source
AI summary
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.